CAR T-Cell Therapy for Mesothelioma in New Phase I Trial
Researchers at Memorial Sloan Kettering in New York are about to try a new kind of CAR T-cell therapy for mesothelioma in human patients. This is the first Phase I trial of the new CAR T-cell approach. The therapy involves removing some of a patient’s T-cells, modifying them, and giving them back to fight cancer. The new CAR T-cell therapy for mesothelioma involves cells that have been modified in new ways. They still seek out cancer cells. But these CAR T-cells are made to last longer and to undermine a primary mesothelioma cell defense mechanism. The FDA approved the study in September. Memorial Sloan Kettering is recruiting mesothelioma patients for it now. T-Cells That Target Mesothelioma Cells CART T-cell therapy…